WCLC 2025 | Updates in EGFRm NSCLC at WCLC 2025: FLAURA2, ACROSS 2 & HARMONi

This morning a few abstracts have been presented and I’m super excited, honestly. The most important ones place themselves in the larger scenario of the evolution of the treatment landscape of a EGFR positive disease. We saw the positive survival updates of the FLAURA2 trial investigating the combination of osimertinib plus chemo against osimertinib alone, and it was positive, complementing the earlier PFS data. And then we saw the update of the ACROSS 2trial investigating aumolertinib and other third-gen TKI plus chemotherapy, and again, this update was positive, therefore broadening the evidence around the utility of combining chemo to a backbone of single-agent third-gen TKI. And then we also saw the broader results of the HARMONi trial investigating bispecific ivonescimab, a bi-specific targeting VEGF and PD-1 combined to the standard chemotherapy against chemotherapy with positive results in the post-progression setting, expanding the post-progression toolkit for patient progression. So general reasoning around this topic is that now we have three clear frameworks for first-line treatment, osimertinib alone, osimertinib plus chemo and amivantamab plus lazertinib. We are sort of spoiled by options. It can be a bit complex, but it’s a good problem to have at the end of the day because we’re moving from the one-size-fits-all to a more personalized approach. Therefore, it’s just more ways to have a more personalized care. So it is time now to onboard patients in the decision-making process right from the beginning and making decisions shared, weighing pros and cons, weighing disease control, the expected to succeed profile, logistics, patient’s priorities and all that. It’s great to have this complexity.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.